The role of 111In Capromab Pendetide (ProstaScintR) immunoscintigraphy in the management of prostate cancer

Leonard M. Freeman, B. R. Krynyckyi, Y. Li, G. Korupulu, K. Saleemi, M. K. Haseman, D. Kahn

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

111In Capromab Pendetide (ProstaScintR) is a whole murine antibody that is reactive with prostate specific membrane antigen (PSMA), a glycoprotein on the surface of normal and abnormal prostate epithelium. It has proven to be of great value in assisting management decisions in prostate cancer patients who initially present with high risk for metastatic spread, or who develop a picture of recurrent disease after surgery or radiation therapy. Patterns of metastatic lymphatic spread have correlated well with autopsy reports in the literature. Unfortunately, other imaging study and/or histologic confirmation of scintigraphic findings has been difficult to obtain. Prostascint's role in predicting durable complete response (DCR) in postoperative patients having salvage radiotherapy to their prostate fossa is very promising. Further investigative work in larger patient populations is needed to confirm these early results.

Original languageEnglish (US)
Pages (from-to)131-137
Number of pages7
JournalQuarterly Journal of Nuclear Medicine
Volume46
Issue number2
StatePublished - Jun 2002

Fingerprint

Prostatic Neoplasms
Prostate
Radiotherapy
Membrane Glycoproteins
Autopsy
Epithelium
Antibodies
Population
Capromab Pendetide
human glutamate carboxypeptidase II

Keywords

  • Antibodies, monoclonal
  • Lymph nodes, radionuclide imaging
  • Prostatic neoplasms, diagnosis
  • Prostatic neoplasms, radionuclide imaging

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Freeman, L. M., Krynyckyi, B. R., Li, Y., Korupulu, G., Saleemi, K., Haseman, M. K., & Kahn, D. (2002). The role of 111In Capromab Pendetide (ProstaScintR) immunoscintigraphy in the management of prostate cancer. Quarterly Journal of Nuclear Medicine, 46(2), 131-137.

The role of 111In Capromab Pendetide (ProstaScintR) immunoscintigraphy in the management of prostate cancer. / Freeman, Leonard M.; Krynyckyi, B. R.; Li, Y.; Korupulu, G.; Saleemi, K.; Haseman, M. K.; Kahn, D.

In: Quarterly Journal of Nuclear Medicine, Vol. 46, No. 2, 06.2002, p. 131-137.

Research output: Contribution to journalArticle

Freeman, LM, Krynyckyi, BR, Li, Y, Korupulu, G, Saleemi, K, Haseman, MK & Kahn, D 2002, 'The role of 111In Capromab Pendetide (ProstaScintR) immunoscintigraphy in the management of prostate cancer', Quarterly Journal of Nuclear Medicine, vol. 46, no. 2, pp. 131-137.
Freeman, Leonard M. ; Krynyckyi, B. R. ; Li, Y. ; Korupulu, G. ; Saleemi, K. ; Haseman, M. K. ; Kahn, D. / The role of 111In Capromab Pendetide (ProstaScintR) immunoscintigraphy in the management of prostate cancer. In: Quarterly Journal of Nuclear Medicine. 2002 ; Vol. 46, No. 2. pp. 131-137.
@article{533d832b65a94340af77fe079d079e22,
title = "The role of 111In Capromab Pendetide (ProstaScintR) immunoscintigraphy in the management of prostate cancer",
abstract = "111In Capromab Pendetide (ProstaScintR) is a whole murine antibody that is reactive with prostate specific membrane antigen (PSMA), a glycoprotein on the surface of normal and abnormal prostate epithelium. It has proven to be of great value in assisting management decisions in prostate cancer patients who initially present with high risk for metastatic spread, or who develop a picture of recurrent disease after surgery or radiation therapy. Patterns of metastatic lymphatic spread have correlated well with autopsy reports in the literature. Unfortunately, other imaging study and/or histologic confirmation of scintigraphic findings has been difficult to obtain. Prostascint's role in predicting durable complete response (DCR) in postoperative patients having salvage radiotherapy to their prostate fossa is very promising. Further investigative work in larger patient populations is needed to confirm these early results.",
keywords = "Antibodies, monoclonal, Lymph nodes, radionuclide imaging, Prostatic neoplasms, diagnosis, Prostatic neoplasms, radionuclide imaging",
author = "Freeman, {Leonard M.} and Krynyckyi, {B. R.} and Y. Li and G. Korupulu and K. Saleemi and Haseman, {M. K.} and D. Kahn",
year = "2002",
month = "6",
language = "English (US)",
volume = "46",
pages = "131--137",
journal = "Quarterly Journal of Nuclear Medicine and Molecular Imaging",
issn = "1824-4785",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "2",

}

TY - JOUR

T1 - The role of 111In Capromab Pendetide (ProstaScintR) immunoscintigraphy in the management of prostate cancer

AU - Freeman, Leonard M.

AU - Krynyckyi, B. R.

AU - Li, Y.

AU - Korupulu, G.

AU - Saleemi, K.

AU - Haseman, M. K.

AU - Kahn, D.

PY - 2002/6

Y1 - 2002/6

N2 - 111In Capromab Pendetide (ProstaScintR) is a whole murine antibody that is reactive with prostate specific membrane antigen (PSMA), a glycoprotein on the surface of normal and abnormal prostate epithelium. It has proven to be of great value in assisting management decisions in prostate cancer patients who initially present with high risk for metastatic spread, or who develop a picture of recurrent disease after surgery or radiation therapy. Patterns of metastatic lymphatic spread have correlated well with autopsy reports in the literature. Unfortunately, other imaging study and/or histologic confirmation of scintigraphic findings has been difficult to obtain. Prostascint's role in predicting durable complete response (DCR) in postoperative patients having salvage radiotherapy to their prostate fossa is very promising. Further investigative work in larger patient populations is needed to confirm these early results.

AB - 111In Capromab Pendetide (ProstaScintR) is a whole murine antibody that is reactive with prostate specific membrane antigen (PSMA), a glycoprotein on the surface of normal and abnormal prostate epithelium. It has proven to be of great value in assisting management decisions in prostate cancer patients who initially present with high risk for metastatic spread, or who develop a picture of recurrent disease after surgery or radiation therapy. Patterns of metastatic lymphatic spread have correlated well with autopsy reports in the literature. Unfortunately, other imaging study and/or histologic confirmation of scintigraphic findings has been difficult to obtain. Prostascint's role in predicting durable complete response (DCR) in postoperative patients having salvage radiotherapy to their prostate fossa is very promising. Further investigative work in larger patient populations is needed to confirm these early results.

KW - Antibodies, monoclonal

KW - Lymph nodes, radionuclide imaging

KW - Prostatic neoplasms, diagnosis

KW - Prostatic neoplasms, radionuclide imaging

UR - http://www.scopus.com/inward/record.url?scp=0036620678&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036620678&partnerID=8YFLogxK

M3 - Article

C2 - 12114876

AN - SCOPUS:0036620678

VL - 46

SP - 131

EP - 137

JO - Quarterly Journal of Nuclear Medicine and Molecular Imaging

JF - Quarterly Journal of Nuclear Medicine and Molecular Imaging

SN - 1824-4785

IS - 2

ER -